| Year |
Citation |
Score |
| 2023 |
Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, et al. Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37289191 DOI: 10.1158/1078-0432.CCR-23-0375 |
0.417 |
|
| 2022 |
Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, et al. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. British Journal of Cancer. PMID 35440668 DOI: 10.1038/s41416-022-01811-9 |
0.388 |
|
| 2022 |
Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, et al. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. Journal of Experimental & Clinical Cancer Research : Cr. 41: 109. PMID 35346313 DOI: 10.1186/s13046-022-02332-2 |
0.352 |
|
| 2021 |
Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Translational Lung Cancer Research. 10: 4095-4105. PMID 35004241 DOI: 10.21037/tlcr-21-437 |
0.417 |
|
| 2021 |
Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, ... ... Cardnell R, et al. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications. 12: 6655. PMID 34789716 DOI: 10.1038/s41467-021-26821-8 |
0.374 |
|
| 2021 |
Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, Oliver TG, Wang J, Byers LA. Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism. 9: 33. PMID 34556188 DOI: 10.1186/s40170-021-00270-9 |
0.332 |
|
| 2021 |
Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. British Journal of Cancer. PMID 34294893 DOI: 10.1038/s41416-021-01476-w |
0.317 |
|
| 2021 |
Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, et al. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34274504 DOI: 10.1016/j.jtho.2021.07.002 |
0.351 |
|
| 2021 |
Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, et al. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34274504 DOI: 10.1016/j.jtho.2021.07.002 |
0.351 |
|
| 2021 |
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. PMID 33482121 DOI: 10.1016/j.ccell.2020.12.014 |
0.327 |
|
| 2021 |
Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC. Cancer Research. PMID 33402388 DOI: 10.1158/0008-5472.CAN-20-1895 |
0.401 |
|
| 2020 |
Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, et al. AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors. Molecular Cancer Research : McR. PMID 33172976 DOI: 10.1158/1541-7786.MCR-20-0414 |
0.398 |
|
| 2020 |
Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, Hillman RT, Cardnell R, Byers L, Frumovitz M. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 30: 1303-1307. PMID 32727929 DOI: 10.1136/Ijgc-2020-001649 |
0.306 |
|
| 2020 |
Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M. Comparative genomics of high grade neuroendocrine carcinoma of the cervix. Plos One. 15: e0234505. PMID 32544169 DOI: 10.1371/Journal.Pone.0234505 |
0.439 |
|
| 2020 |
Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, et al. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32068166 DOI: 10.1016/J.Jtho.2020.01.009 |
0.392 |
|
| 2020 |
Sen T, Milutinovic S, Cardnell RJ, Diao L, Fan Y, Hansen RJ, Strouse B, Hedrick MP, Hassig C, Wang J, Byers LA. Abstract B15: The oral Chk1 inhibitor, SRA737, synergizes with immune checkpoint blockade in small-cell lung cancer (SCLC) Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B15 |
0.426 |
|
| 2020 |
Cargill KR, Cardnell RJ, Fan Y, Wang Q, Diao L, Wang J, Byers LA. Abstract 232: Comprehensive metabolic profiling and vulnerabilities to metabolic inhibitors among small cell lung cancer subtypes Cancer Research. 80: 232-232. DOI: 10.1158/1538-7445.Am2020-232 |
0.462 |
|
| 2020 |
Carroll M, Salvo G, Ramalingam P, Phoolcharoen N, Cardnell R, Byers L, Frumovitz M. PARP and PD-L1 as Potential Therapeutic Targets for Women with Neuroendocrine Cervical Cancer Gynecologic Oncology. 156: e21-e22. DOI: 10.1016/J.Ygyno.2019.11.075 |
0.335 |
|
| 2020 |
Ramkumar K, Stewart C, Gay C, Cardnell R, Diao L, Wang Q, Shen L, Xi Y, Kundu S, Della Corte C, Gibbons D, Wang J, Heymach J, Byers L. 1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer Annals of Oncology. 31: S1015-S1016. DOI: 10.1016/j.annonc.2020.08.1800 |
0.331 |
|
| 2019 |
Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, et al. Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31470128 DOI: 10.1016/J.Jtho.2019.08.009 |
0.424 |
|
| 2019 |
Cardnell RJ, Byers LA, Wang J. Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers. Cancers. 11. PMID 30791396 DOI: 10.3390/Cancers11020239 |
0.478 |
|
| 2019 |
Sen T, Corte CMD, Milutinovic S, Diao L, Cardnell RJ, Hansen RJ, Strouse B, Hedrick MP, Hassig C, Wang J, Byers LA. Abstract LB-148: Combination treatment of the CHK1 inhibitor, SRA737, and low dose gemcitabine demonstrates profound synergy with anti-PDL1 inducing durable tumor regressions and modulating the immune microenvironment in small cell lung cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-148 |
0.426 |
|
| 2019 |
Diao L, Stewart CA, Xi Y, Cardnell RJ, Swisher SG, Roth JA, Glisson BS, Wang J, Heymach JV, Byers LA. Abstract 3772: Inter- and intra-tumoral variations in ASCL1, NEUROD1, and POU2F3 transcriptional programs underlie three distinct molecular subtypes of small cell lung cancers Cancer Research. 79: 3772-3772. DOI: 10.1158/1538-7445.Am2019-3772 |
0.456 |
|
| 2019 |
Corte CMD, Ajpacaja LL, Cardnell RJ, Diao L, Wang Q, Ramkumar K, Stewart AC, Kow RB, Stumpf HE, Fan Y, Wang J, Heymach JV, Byers LA. Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer Molecular Cancer Therapeutics. DOI: 10.1158/1535-7163.Targ-19-B064 |
0.46 |
|
| 2019 |
Heymach C, Cardnell R, Diao L, Wang J, Ng K, Byers L. Abstract B032: Proteomic analysis reveals alterations in apoptotic signaling machinery in HPV-associated cancers and identifies BRD4 and BCL2 as potential therapeutic targets in HPV-positive HNSCCs Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B032 |
0.325 |
|
| 2019 |
Ramkumar K, Corte CMD, Diao L, Cardnell RJ, Papadimitrakopoulou VA, Heymach JV, Wang J, Gibbons DL, Byers LA. Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B024 |
0.516 |
|
| 2019 |
Della Corte C, Ajpacaja L, Cardnell R, Gay C, Wang Q, Shen L, Ramkumar K, Stewart A, Fan Y, Adelman C, Travers J, Wang J, Heymach J, Byers L. Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer Annals of Oncology. 30: v716. DOI: 10.1093/Annonc/Mdz264.013 |
0.354 |
|
| 2019 |
Gay C, Diao L, Stewart C, Xi Y, Cardnell R, Swisher S, Roth J, Glisson B, Wang J, Heymach J, Byers L. OA03.06 ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities Journal of Thoracic Oncology. 14: S213. DOI: 10.1016/J.Jtho.2019.08.421 |
0.478 |
|
| 2018 |
Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30257981 DOI: 10.1158/1078-0432.Ccr-18-1129 |
0.342 |
|
| 2018 |
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018777672. PMID 29906251 DOI: 10.1200/Jco.2018.77.7672 |
0.358 |
|
| 2018 |
Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head & Neck. PMID 29570891 DOI: 10.1002/Hed.25146 |
0.433 |
|
| 2018 |
Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Chalishazar MD, Ireland AS, Huang F, Hu Z, Cardnell RJ, Sen T, Gertz J, Johnson JE, Gazdar AF, Byers LA, DeBerardinis RJ, et al. Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Aacriaslc18-Ia27 |
0.492 |
|
| 2018 |
Hillman R, Cardnell R, Fujimoto J, Byers L, Futreal P, Frumovitz M. Genomic landscape of small cell neuroendocrine cervical cancer Gynecologic Oncology. 149: 626-627. DOI: 10.1016/J.Ygyno.2018.03.026 |
0.388 |
|
| 2017 |
Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR. A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget. 8: 81441-81454. PMID 29113403 DOI: 10.18632/Oncotarget.19888 |
0.475 |
|
| 2017 |
Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, et al. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 8: 73419-73432. PMID 29088717 DOI: 10.18632/Oncotarget.20621 |
0.504 |
|
| 2017 |
Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/Sciadv.1600957 |
0.428 |
|
| 2017 |
Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. PMID 28212573 DOI: 10.18632/Oncotarget.15338 |
0.492 |
|
| 2017 |
Tong P, Cardnell RJ, Su X, Kalu NN, Banerjee U, Bara RO, Johnson FM, Heymach JV, Wang J, Byers LA. Abstract 1560: Differential sensitivity analysis for resistant malignancies (DISARM), a novel approach for drug screen analysis, identifies common candidate drugs across platinum-resistant cancer types Cancer Research. 77: 1560-1560. DOI: 10.1158/1538-7445.Am2017-1560 |
0.33 |
|
| 2017 |
Byers LA, Krug L, Waqar S, Dowlati A, Hann C, Chiappori A, Owonikoko T, Woo K, Bensman Y, Hurtado B, Cardnell R, Diao L, Fan Y, Fujimoto J, Rodriguez-Canales J, et al. MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial Journal of Thoracic Oncology. 12: S406-S407. DOI: 10.1016/J.Jtho.2016.11.466 |
0.413 |
|
| 2016 |
Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. Plos One. 11: e0152584. PMID 27055253 DOI: 10.1371/Journal.Pone.0152584 |
0.458 |
|
| 2016 |
Cardnell RJ, Li L, Masrorpour F, Niu H, Ecsedy J, Wang J, Byers LA. Abstract 3887: Proteomic profiling identifies cMyc and TTF1 as biomarkers of response to the aurora kinase inhibitor alisertib in small cell lung cancer (SCLC) Cancer Research. 76: 3887-3887. DOI: 10.1158/1538-7445.Am2016-3887 |
0.495 |
|
| 2016 |
Stewart CA, Tong P, Cardnell R, Sen T, Masrorpour FM, Fan Y, Wang J, Byers LA. Abstract 3870: SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC) Cancer Research. 76: 3870-3870. DOI: 10.1158/1538-7445.Am2016-3870 |
0.541 |
|
| 2016 |
Cardnell R, Tong P, Giri U, Gudikote J, Banerjee U, Kalu N, Fan Y, Nilsson M, Johnson F, Tran H, Wang J, Heymach J, Byers L. A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL European Journal of Cancer. 69: S82. DOI: 10.1016/S0959-8049(16)32840-4 |
0.35 |
|
| 2015 |
Mak M, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26420858 DOI: 10.1158/1078-0432.Ccr-15-0876 |
0.474 |
|
| 2015 |
Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25878335 DOI: 10.1158/1078-0432.Ccr-14-3286 |
0.437 |
|
| 2015 |
Rabender CS, Alam A, Sundaresan G, Cardnell RJ, Yakovlev VA, Mukhopadhyay ND, Graves P, Zweit J, Mikkelsen RB. The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression. Molecular Cancer Research : McR. 13: 1034-43. PMID 25724429 DOI: 10.1158/1541-7786.Mcr-15-0057-T |
0.323 |
|
| 2015 |
Mak MP, Diao L, Tong P, Wang J, Ng PKS, Cardnell R, Hayes DN, Robertson G, Myers J, El-Naggar AK, William WN, Coombes KR, Weinstein JN, Mills GB, Heymach J, et al. Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers. Journal of Clinical Oncology. 33: 6016-6016. DOI: 10.1200/Jco.2015.33.15_Suppl.6016 |
0.459 |
|
| 2015 |
Mukherjee S, Mitani Y, Cardnell R, Fan YH, Diao L, Wang J, El-Naggar AK, Byers LA. Abstract LB-111: Comprehensive proteomic analysis of salivary gland cancer subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-111 |
0.387 |
|
| 2015 |
Shelly J, Cardnell RJ, Masrorpour F, Diao L, Wang J, Byers L. Abstract 7: PARP and Bcl-2 co-inhibition in small cell lung cancer (SCLC) Cancer Research. 75: 7-7. DOI: 10.1158/1538-7445.Am2015-7 |
0.509 |
|
| 2015 |
Valliani AA, Sen T, Masrorpour F, Diao L, Cardnell RJ, Wang J, Glisson BS, Piwnica-Worms H, Gibbons DL, Byers LA. Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC) Cancer Research. 75: 5316-5316. DOI: 10.1158/1538-7445.Am2015-5316 |
0.526 |
|
| 2015 |
Balaji K, Cardnell R, Diao L, Tong P, Mak M, Fan YH, Masrorpour F, Warner SL, Bearss DJ, Wistuba I, Mills GB, Heymach J, Keyomarsi K, Wang J, Byers LA. Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma Cancer Research. 75: 3579-3579. DOI: 10.1158/1538-7445.Am2015-3579 |
0.497 |
|
| 2015 |
Mukherjee S, Glisson BS, Minna JD, Cardnell RJ, Girard L, Gazdar A, Diao L, Wang J, Byers LA. Abstract 2961: Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC Cancer Research. 75: 2961-2961. DOI: 10.1158/1538-7445.Am2015-2961 |
0.457 |
|
| 2015 |
Feng Y, Yu K, Cardnell R, Ru Y(, Wang E, Wang J, Post LE, Byers LA, Shen Y(. Abstract A37: Talazoparib predictive biomarker analysis in human small cell lung cancer cells and PDX tumors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A37 |
0.532 |
|
| 2014 |
Cardnell RJ, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2237. PMID 24687924 DOI: 10.1158/1078-0432.CCR-13-3391 |
0.355 |
|
| 2014 |
Cardnell R, Feng Y, Diao L, Fan Y, Masrorpour F, Mukherjee S, Shen J, Wang J, Byers L. 243 Modulation of PI3K/mTOR pathway following PARP inhibition in small cell lung cancer European Journal of Cancer. 50: 81-82. DOI: 10.1016/S0959-8049(14)70369-7 |
0.383 |
|
| 2014 |
Feng Y, Post L, Cardnell R, Byers L, Wang B, Shen Y. 242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models European Journal of Cancer. 50: 81. DOI: 10.1016/S0959-8049(14)70368-5 |
0.378 |
|
| 2013 |
Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6322-8. PMID 24077350 DOI: 10.1158/1078-0432.Ccr-13-1975 |
0.458 |
|
| 2013 |
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 279-90. PMID 23091115 DOI: 10.1158/1078-0432.Ccr-12-1558 |
0.37 |
|
| 2013 |
Cardnell R, Diao L, Wang J, Bearss D, Warner S, Fan YH, Giri U, Story MD, Weinstein JN, Coombes KR, Williams MD, Genome Atlas Reseach Network TC, Wistuba II, Mills GB, Myers J, et al. An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 31: 6011-6011. DOI: 10.1200/Jco.2013.31.15_Suppl.6011 |
0.493 |
|
| 2013 |
Cardnell RJ, Feng Y, Diao L, Fan YH, Wang J, Shin Y, Minna JD, Heymach JV, Byers LA. Abstract 2489: Proteomic profiling identifies PI3K and DNA repair pathways as potential markers of response to PARP inhibitor BMN673 in SCLC. Cancer Research. 73: 2489-2489. DOI: 10.1158/1538-7445.Am2013-2489 |
0.475 |
|
| 2006 |
Cardnell RJ, Nogare DE, Ganetzky B, Stern M. In vivo analysis of a gain-of-function mutation in the Drosophila eag-encoded K+ channel. Genetics. 172: 2351-8. PMID 16452147 DOI: 10.1534/Genetics.105.048777 |
0.515 |
|
| Show low-probability matches. |